NCT07348107 2026-01-16
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1 Not yet recruiting
Clinical Trials
89 trialsNCT01409161 2025-12-17
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07187505 2025-09-23
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
Phase NA Active not recruiting
NCT06778187 2025-06-10
Oral-ATO for TP53-mutated Myeloid Malignancies
The University of Hong Kong
Phase 2 Recruiting
NCT03503864 2025-05-21
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT06933394 2025-04-18
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT02688140 2025-02-26
TUD-APOLLO-064
Technische Universität Dresden
Phase 3 Completed
NCT06450145 2024-06-10
APL
Zhejiang Provincial People's Hospital
Phase NA Recruiting
NCT04793919 2024-04-15
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2 Recruiting
NCT06088030 2024-01-03
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT03855371 2022-11-04
PANDA-T0
Ruijin Hospital
Phase 1 Unknown
NCT05497310 2022-10-26
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 1/2 Unknown
NCT00482833 2022-10-12
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Completed
NCT03624270 2022-10-04
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
Phase 2 Unknown
NCT01014546 2022-07-22
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Roswell Park Cancer Institute
Phase 1 Terminated
NCT05297123 2022-03-28
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
First Affiliated Hospital Xi'an Jiaotong University
Phase 1 Unknown
NCT01404949 2021-11-30
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02899169 2021-09-08
APL16
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT02190695 2021-05-19
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Fox Chase Cancer Center
Phase 2 Completed
NCT04869475 2021-05-13
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Ruijin Hospital
Phase 2 Unknown
NCT01470248 2021-02-17
Study of Arsenic Trioxide in Small Cell Lung Cancer
Emory University
Phase 2 Completed
NCT04695223 2021-01-06
Arsenic Trioxide for Structural p53 Mutations
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02699723 2020-10-22
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
Stanford University
Phase EARLY_PHASE1 Withdrawn
NCT00469209 2020-09-24
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00234000 2020-07-31
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT04489706 2020-07-28
Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
Ruijin Hospital
Phase NA Unknown
NCT00274820 2020-07-27
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00275067 2020-02-25
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
Northwestern University
Phase 1/2 Unknown
NCT01987297 2019-08-19
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
Phase 4 Unknown
NCT00571116 2019-08-07
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
University of California, Irvine
Phase 1 Terminated
NCT00413166 2019-05-07
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00006091 2018-11-14
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01397734 2018-09-06
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT00004149 2018-08-17
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Albert Einstein College of Medicine
Phase 2 Completed
NCT00104806 2018-08-10
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01791894 2018-06-08
ATO
Stanford University
Phase 1/2 Completed
NCT01835288 2018-05-21
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 2 Withdrawn
NCT00118196 2018-05-11
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Medical University of South Carolina
Phase 2 Terminated
NCT03381781 2018-01-04
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
Phase 2 Unknown
NCT01428128 2017-12-13
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01184053 2017-06-14
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00128596 2017-04-27
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 2 Completed
NCT02956772 2017-02-23
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Hunan Provincial People's Hospital
Phase 2 Unknown
NCT00006021 2016-12-15
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
University of Miami
Phase 1/2 Completed
NCT00449137 2016-12-15
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
University of Miami
Phase 1 Completed
NCT00504101 2016-12-15
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Phase 1 Withdrawn
NCT02757040 2016-04-29
Combination of Ibrutinib and As2O3 in the Treatment of CLL
Peking University People's Hospital
Phase 3 Unknown
NCT00582400 2016-02-19
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
The University of Texas Medical Branch, Galveston
Phase 2 Terminated
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00024258 2015-11-25
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed